Nystatin enhances the antitumor and antiangiogenic efficacies of endostatin. When tumor volume reached 0.1 cm³, A549 tumor–bearing mice received daily injections of saline, nystatin (4 mg/kg intraperitoneally), endostatin (4 mg/kg intravenously), or a combination of nystatin and endostatin for 14 days. (A) Tumor volume was measured every 3 days. Tumors (n = 6/group) were resected at 14 days, weighed (B), and applied to immunofluorescent analysis of anti-CD31 blood vessel staining using a Nikon A1 microscope (20×/0.75 NA air objective) (C) and blood vessel area quantification (D). *P < .05 and **P < .01. Error bars represent SEMs.